Barclays initiated coverage of GoodRx (GDRX) with an Underweight rating and $3 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
- GoodRx price target lowered to $3 from $3.40 at BofA
- GoodRx announces weight loss telemedicine subscription, Novo Nordisk pact
- Novo launches introductory self-pay offer for Wegovy, Ozempic for $199 per month
- GoodRx price target lowered to $5 from $6 at JPMorgan
- GoodRx price target lowered to $6 from $7 at TD Cowen